Healthcare resource use and associated costs in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
Fiche publication
Date publication
novembre 2022
Journal
Respiratory medicine and research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BONNIAUD Philippe
Tous les auteurs :
Cottin V, Spagnolo P, Bonniaud P, Dalon F, Nolin M, Kirchgässler KU, Van Ganse E, Belhassen M
Lien Pubmed
Résumé
Real-world data regarding health-care resource use (HCRU) and costs of idiopathic pulmonary fibrosis (IPF) are scarce. In France, at the time of the study, pirfenidone and nintedanib were reimbursed for documented IPF only, with similar reimbursement criteria with regard to disease characteristics, prescription through a dedicated form, and IPF diagnosis established in a multidisciplinary setting. The objective of this study was to evaluate costs related to HCRU in patients newly treated with pirfenidone or nintedanib in 2015-2016, in France, using the exhaustive claims data of the French National Health System.
Mots clés
Antifibrotics, Costs, Healthcare resource use, Idiopathic pulmonary fibrosis
Référence
Respir Med Res. 2022 11 23;83:100951